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Abstract
Background—Provider-based research networks (PBRNs) make clinical trials available in
community-based practice settings, where most people receive their care, but provider
participation requires both financial and in-kind contributions.
Purpose—This study explores whether providers believe there is a business case for
participating in PBRNs and what factors contribute to the business case.
Methodology/Approach—We use a multiple case study methodology approach to examine the
National Cancer Institute's Community Clinical Oncology Program, a longstanding federally
funded PBRN. Interviews with 41 key informants across five sites, selected on the basis of
organizational maturity, were conducted using a semi-structured interview guide. We analyzed
interview transcripts using an iterative, deductive process to identify themes and subthemes in the
data.
Findings—We found that a business case for provider participation in PBRNs may exist if both
direct and indirect financial benefits are identified and included in the analysis, and if the time
horizon is long enough to allow those benefits to be realized. We identified specific direct and
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indirect financial benefits that were perceived as important contributors to the business case and
the perceived length of time required for a positive return to accrue.
Practice Implications—As the lack of a business case may result in provider reluctance to
participate in PBRNs, knowledge of the benefits we identified may be crucial to encouraging and
sustaining participation, thereby preserving patient access to innovative community-based
treatments. The results are also relevant to federally-funded PBRNs outside of oncology or to
providers considering participation in any clinical trials research.
Keywords
clinical trials; provider-based research network; oncology; return on investment; business case
INTRODUCTION
Clinical trials are research studies that test cutting-edge therapies developed to prevent,
detect, and treat diseases (National Cancer Institute 2011). With new discoveries in basic
science, it has become increasingly important for clinical trials to be conducted not only in
academic medical centers, but also in community-based hospitals and physician practices
where most people receive their care (Minasian et al. 2010). Provider-based research
networks (PBRNs) -- collaborative partnerships between community-based providers and
research institutions -- provide a promising model for increasing community-based provider
participation in clinical trials research, and may therefore be a critical component of
expanding access to clinical trials and the latest innovations in medical care.
However, participation in clinical trials research can require substantial investments of time
and money by community-based providers (Ryan et al. 2011; Holler, Forgione, Baisden,
Abramson & Calhoon, 2011). If providers are faced with resource constraints, clinical and
quality-improvement programs without a clearly identifiable business case, or financial
return on investment, are at risk of either not gaining or not retaining organizational support
(Leatherman, et al., 2003; Institute of Medicine, 2008). Thus, the lack of an established
business case may result in provider reluctance to participate in clinical trials, or in broader
research innovations such as PBRNs.
Currently little is known about whether, or under what conditions, a business case for PBRN
participation exists. To fill this gap, this study sought to learn: (1) whether providers believe
there is a business case for participating in a PBRN; (2) if so, what factors contribute to the
business case; and (3) whether or not providers believe it is important to establish a business
case to generate organizational support for initiating or sustaining PBRN participation. To
answer these questions, we conducted a multi-site case study of the National Cancer
Institute's (NCI) Community Clinical Oncology Program (CCOP).
Our study contributes to the existing business case literature that has investigated
investments in clinical or quality-improvement initiatives in health care by being the first to
explore whether and under what conditions a business case exists for provider participation
in clinical trials through a PBRN. Further, this study identifies specific direct and indirect
financial benefits of provider participation in clinical trials research through an established
PBRN, and the perceived time frame required for these benefits to accrue. Since the CCOP
may serve as a model for future PBRNs, findings from this study can inform decisions at
both the organization and policy levels, and help encourage expansion and sustainability of
clinical trials research in community-based settings.
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NCI's Community Clinical Oncology Program
The CCOP is a federally-funded PBRN that plays an essential role in the National Cancer
Institute's (NCI's) effort to increase enrollment in cancer clinical trials. There are currently
47 funded CCOP organizations (i.e., local networks of hospitals and oncologists), and 16
funded Minority-based CCOP organizations throughout the United States, collectively
representing 400 hospitals and 3,520 physicians (National Cancer Institute, 2011). These
CCOP organizations provide the research infrastructure and support to make NCI-sponsored
clinical trials available in community-based practice settings. The NCI's CCOP model is
regarded as a highly successful example of a federally-funded PBRN, with community-
based CCOP organizations generating approximately one-third of the total patient
enrollments to NCI-sponsored clinical trials (National Cancer Institute, 2011b; Cobau, 1994;
Minasian et al., 2010). Because of its success, the NCI's CCOP program has already served
as a model for other federally-funded PBRNs such as the National Institute on Drug Abuse's
Clinical Trials Network and the National Institute of Allergy and Infectious Disease's
Community Program for Clinical Research on AIDS, and may continue to serve as a model
for future PBRNs (Lamb, Greenlick & McCarty 1998).
Over the past decade, the NCI has provided approximately $90 million annually to CCOP
organizations and research bases through a competitive grant process. In 2010, the average
annual grant awarded by the NCI to a CCOP organization was $890,000 (National Cancer
Institute, 2011). While this federal support covers a substantial portion of direct costs
associated with participating in the CCOP, the grant is not intended to cover all of the costs
needed to conduct NCI-sponsored trials (Minasian et al., 2010). Instead, CCOP
organization-affiliated hospitals and/or physician practices (henceforth referred to as
“CCOP-affiliated providers”) are expected to contribute both financially and in-kind to
support the research infrastructure. Thus, for many community-based providers,
participation in a CCOP organization requires substantial financial investment, far greater
than the level of federal grant funding. In return for their investment, CCOP-affiliated
providers have the potential to realize both clinical and financial benefits from CCOP
participation.
Clinical benefits of CCOP participation include access to the most novel and innovative
cancer treatment therapies. Two recent studies have demonstrated that CCOP-affiliated
hospitals and providers more rapidly adopted evidence-based cancer therapies than did non-
CCOP affiliated providers. Specifically, Carpenter et al. (2011) observed that hospitals
affiliated with NCI's clinical cooperative groups, a cohort that includes CCOP-affiliated
hospitals, more rapidly adopted sentinel lymph node biopsy (an innovation in early-stage
breast cancer treatment) than did hospitals with no such affiliation (Carpenter, Reeder-
Hayes, Bainbridge, Meyer, Amos, Weiner, Godley 2012). In another study, Carpenter and
colleagues observed that Stage III colon cancer patients seen by CCOP providers were more
likely to receive the innovative therapy oxaliplatin and guideline-concordant care than were
similar patients receiving care from other community providers (Carpenter, Meyer, Wu,
Qaqish, Sanoff, Goldberg, Weiner 2012). Yet while the clinical return on investment has
been well established, the financial return on investment, or business case, is less clear.
CCOP Organizations and CCOP-Affiliated Provider Relationships
To be a CCOP is to be funded through a Cooperative Agreement with the NCI for the
purpose of accruing patients onto cancer treatment and prevention clinical trials. A CCOP
organization may be structured as a single community organization, or as a consortium of
community-based hospitals and physician practices (National Cancer Institute, 2011). As a
result, the organizational structure and financial relationships between providers and CCOP
organizations are varied. CCOP organizations are often housed within one of their CCOP-
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affiliated providers (typically the CCOP-affiliated hospital or health system); however, they
may also exist independent of a specific provider.
CCOP organizations are led by a physician Principal Investigator (PI) who provides local
program leadership. CCOP staff members typically include an associate PI, a program
administrator, research nurses or clinical research associates, data managers, and regulatory
specialists. These staff members coordinate the review and selection of new clinical trial
protocols for CCOP participation, disseminate protocol updates to the participating
physicians, and collect and submit study data. CCOP-affiliated physicians accrue or refer
participants to clinical trials, and typically include medical, surgical and radiation
oncologists, general surgeons, urologists, gastroenterologists, and primary care physicians.
CCOP-affiliated physicians, through their membership in CCOP research bases, also
participate in the development of clinical trials by proposing study ideas, providing input on
study design, and occasionally, serving in the role of PI or co-PI for a clinical trial.
To help support participation in research, NCI trials are deliberately designed to comply
with standards of care; as a result, reimbursement for the direct costs of cancer treatment can
often be obtained from private insurers and Medicare. Insurers and third-party payers do not,
however, reimburse for the costs of research infrastructure (e.g., research nurses, clinical
research associates, data managers, etc.). To help support the infrastructure costs, NCI grants
funds are provided “up-front” to CCOP organizations, prior to enrolling patient in clinical
trials, with the expectation that CCOP organizations will meet certain accrual goals.
Although there are rules about the types of costs that can be covered, CCOP organizations
have flexibility to allocate the grant funds to support different configurations. The grants do
not, however, nor are they intended to fully fund these research costs. Rather, the NCI
expects the participating institutions to share in the support of the research activity. For
example, a CCOP organization may require a membership fee from affiliated CCOP-
providers to participate in the CCOP or, more commonly, hospitals that house CCOP
organizations may cover a portion of the CCOP costs.
Costs that are not directly offset by the CCOP grant funds often include indirect costs, such
as information technology support, physical space, regulatory or compliance support, and
financial management support. These activities are not revenue-generating, and therefore
must be offset by other financial benefits for a business case to exist. In the past, financial
slack allowed providers to direct funds to non-revenue generating activities and still remain
financially viable; however, with the changing financial climate for medical care, the
existence of a business case may be increasingly relevant to CCOP-affiliated providers who
must make the decision to invest in the CCOP organization. Therefore, our study focuses on
the business case, or financial return on investment of CCOP participation, from the
perspective of the CCOP-affiliated providers and not the CCOP organization.
CONCEPTUAL FRAMEWORK
In the standard finance literature, the identification of a business case, or financial return on
investment (ROI), is a primary decision criterion for any type of investment. The capital
budgeting process systematizes the analysis and ranking of projects subject to financing
constraints. Most projects are subjected, at a minimum, to a discounted cash flow analysis
that shows the contribution of the project to the overall value of the organization. Although
projects without a positive financial return may be undertaken, in total, the portfolio of
projects must at least break-even for the organization to remain financially viable (Wheeler
and Clement 1998, Cleverly 1995). Over time, reimbursement has failed to keep pace with
rising health care costs, straining the profitability of many health care organizations
(Speilman 2012) and limiting the capital available for investment. As capital is constrained,
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projects that might once have been undertaken for their contribution to the organization's
mission are likely to be held to more stringent standards for financial return.
The application of a return-on-investment criterion to potential investments in clinical or
quality-improvement programs in health care becomes challenging as many of these
programs generate little to no revenue that can be directly attributed to the initiative. Indeed,
the health care literature has established that a business case for clinical or quality-
improvement related initiatives such as electronic health record implementation or the
introduction of high-performance workforce management practices in health care is largely
driven by the consideration of indirect financial benefits, or benefits that occur incidental to
the initiative but that cannot be directly traced to the program (Bailet & Dyer 2003; Song,
Robbins, Garman, & McAlearney, 2011b; Song, McAlearney, Robbins, & McCullough,
2011).
Recognizing this, we use the operational definition of the “business case” for health
improvement interventions defined by Leatherman and colleagues to frame our study design
and analysis. Leatherman et al. state that “a business case for a health care improvement
intervention exists if the entity that invests in the intervention realizes a financial return on
its investment in a reasonable time frame, using a reasonable rate of discounting. This may
be realized as `bankable dollars' (profit), a reduction in the losses for a given program or
population, or avoided costs.” Leatherman and colleagues further add that “a business case
may exist if the investing entity believes that a positive indirect effect on the organization
function and sustainability will accrue within a reasonable time frame” (Leatherman, et al.
2003, p. 18).
Using this definition, we sought to identify and classify both the direct financial benefits of
participation in clinical trials through a PBRN, as well as the indirect financial benefits,
from the provider's perspective. We define direct financial benefits as those that involve
actual cash transfers between parties that are directly attributable to the CCOP organization
(e.g., NCI grant funding). In contrast, indirect financial benefits are those that accrue to
providers as a result of their affiliation with the CCOP organization, but that are less easy to
monetize because they are not characterized by circumscribed cash transfers or are not
directly linked with CCOP activities that generate cost (e.g., benefits described as “non-
financial” benefits).
METHODS & ANALYSIS
We investigated the business case for provider participation in the CCOP as a key
component of a larger exploratory study of motives for CCOP participation among CCOP-
affiliated providers. Our study was conducted using a multi-site case study methodology
(Maxwell, 2005; Yin, 2008) and used key informant interviews as the basis for our
qualitative data collection (Yin, 2008; Edmonson & McManus, 2007).
Case Study Site Selection
Sites were selected as part of a two-stage process. The first stage focused on an assessment
of CCOP variability in terms of size, organizational structure and organizational maturity.
Based on this first stage assessment and the business case objectives of our study, we
determined that organizational maturity and willingness to participate in our research study
would serve as the primary criteria for the second stage site selection. Thus, we specifically
selected sites that represented nascent to very mature CCOP organizations. Selection based
on differences in organizational maturity ensured variation in perspectives with respect to
initial investment costs, and ongoing costs and returns associated with starting and
sustaining a CCOP organization. Thus, our final study sample included five sites, two of
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which had been operating as CCOP organizations for over 10 years, two of which had been
operating as CCOP organizations between 5 and 10 years, and one of which was an
organization that had recently applied to the NCI, but had not yet become a CCOP
organization. Because the NCI requires CCOP applicants to demonstrate their ability to
conduct clinical trials research, all of the sites in our study report accruals to NCI-sponsored
clinical trials.
Data Collection
Key informant interviews were the primary source of data for these analyses. We developed
a list of targeted key informants based on job title or role within the CCOP or provider
organization. We then worked with the CCOP organization administrator at each study site
to identify potential participants based on this list. We conducted interviews with 41 key
informants across the five study sites. Our key informants included CCOP organization
administrators, principal investigators, physicians, nurses, and hospital accounting and
finance personnel. Detailed information on the study sites, labeled A-E to maintain
confidentiality, is presented in Table 1.
The key informant interviews lasted 30–60 minutes, with nearly all of the interviews held
via telephone with at least two study investigators. To ensure consistency in the data
collection process, key informant interviews were conducted using a semi-structured
interview guide. We pilot tested a draft interview guide to ensure that interview questions
were salient and lacked ambiguity. After pilot testing, we revised the interview guide prior
to use in our study.
Our final interview guide included specific questions about business case considerations
such as “What, if any, sources of revenue are associated with CCOP participation?”; “Do
you think there is, or could be, a positive business case for your organization's participation
in the CCOP?”; and, “How has your organization benefitted from CCOP participation?”
Depending on the respondent's level of business case knowledge and expertise, we probed
further and asked more in-depth questions such as “What kind of impact has the CCOP had
on your organization? Is this impact measureable?” All interviews were recorded and
transcribed verbatim, and then reviewed and verified by the study investigators.
Analyses
We analyzed interview data iteratively using the constant comparative method (Miles &
Huberman, 1994; Strauss & Corbin, 1998). Data were coded initially based on questions
posed in the interview guide, with additional codes introduced as themes and patterns
emerged in the data. A team consisting of a study investigator and two coders trained in
qualitative methods met regularly to review, redefine, and create additional codes as themes
and patterns emerged in the data. We used Atlas.ti, Version 6, to support our coding and
qualitative analyses (Scientific Software Development, 2009).
We analyzed a subset of the data that specifically addressed business case considerations for
provider participation in the CCOP. This included data that reflected both direct responses to
the business case questions as well as unprompted comments related to the business case.
The research team categorized the themes that we found in the answers associated with the
business case through an iterative process. We defined themes and sub-themes that emerged
from these responses when we found confirmation across at least three study sites, and
agreement among the members of the analysis team. A concurrent review of the literature
helped us to compare, validate, and extend our findings where appropriate (Glaser &
Strauss, 1967).
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While none of the informants in our study explicitly reported financial returns as a primary
motive for CCOP participation, we found there was a widespread belief that a business case
could exist for provider participation in the CCOP. We identified two main themes related to
the potential existence of a business case: 1) the existence of a business case depended on
the relevant time frame under consideration, and 2) the business case depended on the
consideration of both direct and indirect financial benefits to the CCOP-affiliated provider.
Within the second theme we also identified sub-themes involving the direct and indirect
financial returns to CCOP participation.
The Business Case and Relevant Time Frame
Most informants reported the belief that a positive business case would be unlikely in the
short-term, defined as less than five years, but that it could exist over the long run. One
research nurse in a mature CCOP organization explained, “Well, I know that in reality we
have to make a long-term commitment because you're not going to see too much in the short
term. You really have to be committed to the CCOP for the long term to be able to see a
return.” Consistent with this sentiment, informants at the site that recently applied to become
a CCOP organization expected their investment would yield returns over the long-term. A
senior administrator at this site explained, “You mean a net positive return? Yeah, I think so
-- over time. It's not anything we're looking to turn around in the next three years or so, but
my hope would be that if in the next five years, if we haven't broken neutral, maybe we've
gotten to the point where we're doing things more efficiently and reducing our costs and
having a higher accrual rate so we're drawing in more revenue.” Additional representative
quotes supporting this theme are presented in Table 2.
A minority of informants reported that they believed there was a positive business case in
the short-term, and cited the grant funding provided by NCI along with reimbursement from
health insurers, which are obligated to pay for standard-of-care treatments, as sufficient
drivers of the short-term business case. Receipt of the grant funds “up-front” was viewed as
advantageous in terms of planning and strategic management practices. An administrator at
one site stated, “I think that having that money handed to you at the beginning of the process
would certainly enable you to make some other choices or to be able to cover some of the
expenses that you may have to be shifting around throughout the process while you're
waiting for that reimbursement later on.” Similarly, another administrator stated, “We don't
do Phase 1 trials, and so the Phase 2 and Phase 3 trials that we have are standard of care. So
the majority of it can be billed to the person's insurance. And so I do think that if we manage
things well we could at least, yeah, I do think we could have a positive [ROI].”
Direct and Indirect Financial Benefits
The second theme that emerged around establishing the business case was the importance of
both direct and indirect financial returns from CCOP participation. Informants across the
study sites believed a business case for CCOP participation existed if both direct and
indirect financial benefits were considered. As one administrator explained, “Yes, I think
so…I think [affiliated hospital] is aware that there is a positive outcome—both financially
and non-financially—for having the CCOP here. I'm not sure that everybody in this facility
is knowing of that, but we have the right people that know.” Similarly, another administrator
agreed that a business case existed, but conceded, “It's a difficult one [ROI] to measure in
direct terms… I certainly think it brings a lot of positive, un-measurable [sic] positive
benefits to our organization.” However, as we further explored this theme of direct and
indirect financial benefits' contributions to the business case, several subthemes also
emerged, as we describe next.
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Direct Financial Benefits—We characterized two subthemes involving direct financial
benefits contributing to the business case for provider participation in the CCOP
organization: 1) grant funding from NCI, and 2) access to additional revenues from
pharmaceutical industry trials.
1) Grant Funding from NCI: The most obvious direct financial benefit from CCOP
participation was the grant funding received from the NCI. CCOP organizations are awarded
grant funds based on expected annual patient accruals to clinical trials. The current funding
is approximately $2,000 per patient enrolled in a clinical trial. As discussed earlier, these
funds are not intended to cover the full costs of conducting clinical trials, and informants in
our study consistently acknowledged that the current reimbursement provided by NCI was
insufficient to cover the costs of CCOP participation. As one stated, “Everybody knows that
basically the per-case reimbursement that you get for putting people on cooperative group
[NCI-sponsored] trials probably isn't going to quite pay for the pay lines.” However, among
the CCOP organizations included in our study, there was considerable variability with
respect to how much of the total CCOP operating costs could be covered by the grant. One
site reported that the NCI grant covered as much as 90% of the total CCOP organization
costs. In contrast, another site reported that the NCI grant covered “46–48% of our budget,
and the remainder is made up by [the CCOP-affiliated hospital].” Despite this variation,
interviewees across all sites consistently noted that NCI grant funds provided a level of
financial stability and predictability to the CCOP-affiliated provider's research infrastructure
that was valued.
2) Access to Pharmaceutical Industry Trial Revenues: The ability to participate in
pharmaceutical industry-sponsored trials was also identified as a direct financial benefit
associated with CCOP participation. Pharmaceutical industry-sponsored trials tend to be
more lucrative than NCI-sponsored trials because providers have flexibility to negotiate
reimbursement rates that will cover all of their costs, including start-up costs associated with
starting a new clinical trial (e.g., internal review board approval, other regulatory processes,
etc.). In contrast, the reimbursement rate for NCI-sponsored trials is a fixed amount per
patient enrollment. Providers suggested that being affiliated with a CCOP organization made
them more competitive with respect to their abilities to participate in industry trials.
Specifically, they cited that they could leverage the existing CCOP infrastructure and
demonstrated success with conducting federally-sponsored clinical trials when negotiating
with pharmaceutical companies to thus make themselves more competitive and more
attractive participants for the more lucrative pharmacy industry-sponsored clinical trials.
The financial contribution of industry trials was noted as an important benefit in four of the
study sites. As one senior oncology administrator explained, “Since we have such a huge
volume of patients, we do drug-sponsored clinical trials where the reimbursement covers the
patient's costs, maybe a hair more, and can offset the rest of the infrastructure.” Another
CCOP administrator was more specific about the contribution of industry trials to the
CCOP-affiliated provider: “For example, this year we overspent the [CCOP] grant by
$240,000, meaning it did not cover all of our basic costs that we needed to be covered under
the grant. But in pharmaceutical, we made $600,000 in revenue. So that $600,000 in revenue
makes up for us losing on the other side, and that what's really helped us with the
institution.” This administrator went on to explain how the CCOP-affiliated providers'
management went from the sentiment of “oh gosh, you know research is just a drain on the
finances and we can't afford to continue to support this” to “Great! You know we are going
to make revenue from research.”
In addition to financial considerations, providers reported that they participated in
pharmaceutical industry-sponsored clinical trials because it clinically “made sense” given
Song et al. Page 8













their patient populations and given their existing clinical trial portfolios. Thus, participation
in industry-sponsored trials was a strategic decision based on overall fit in the CCOP-
affiliated providers' clinical trial portfolio, and as a means to support the research
infrastructure for these providers. It is important to note that since federal funds cannot be
used to directly support industry-sponsored trials, separate accounting practices and proper
oversight must be maintained to ensure compliance. This was the primary reason why one of
the sites in our study decided to discontinue participation in industry-sponsored trials.
Indirect Financial Benefits—The second key consideration for the business case is the
indirect financial benefits, or returns incidental to participation that do not generate direct,
circumscribed cash flows to the CCOP-affiliated provider. Four sub-themes emerged as we
probed to identify, specifically, what CCOP-affiliated providers characterized as indirect
financial benefits of CCOP participation.
1) Downstream Revenue: Downstream revenue is not the revenue earned at the initial
encounter, but the revenue that arises from providing additional services at a later time
throughout the organization (Petersen, 2007). For CCOP-affiliated providers, downstream
revenue is the revenue earned from providing services to patients enrolled in clinical trials
(primarily ancillary services) that are either directly or indirectly related to, but not covered
by, the clinical trial protocol. Across all study sites, downstream revenue was consistently
cited as a primary indirect financial benefit of CCOP participation. Only one study site
reported conducting a formal study of downstream revenue; as described by an administrator
at this site, “We actually did a data sort and came up with all the patients that had been
enrolled; registry studies and everything. And we provided that to financial affairs and said,
`please do a downstream revenue project for us.' And so they did. That downstream revenue
project kind of catapulted us forward. As sort of the leader of the oncology service line, [the
CCOP organization] became a major player.” Although CCOP-affiliated providers at the
remaining four sites had not conducted any formal analyses of downstream revenues, there
was a consistent perception that downstream revenue was a significant factor. One physician
conceded, “It [downstream revenue] is hard to measure and track, but it's there. We wouldn't
be able to be in this business if it weren't.”
2) Market Share: A second sub-theme related to the indirect financial benefits of CCOP
participation was the impact on the CCOP-affiliated provider's market share. Informants
described how CCOP participation contributed to the market share for the CCOP-affiliated
provider by both attracting new patients and keeping patients in the local market. Informants
across all study sites perceived that the ability to offer clinical trials through the local CCOP
organization brought new patients into the system that may have otherwise sought care
elsewhere. A physician summarized this explaining, “I think it [CCOP organization] makes
the practice stronger and it keeps people coming to the center. And so you get a lot of
indirect [benefits] from it, but nothing direct. I think that when you're competing against
major cancer centers and patients have the ability to get on the Internet and to look around at
other places, it allows you to say, `well, you can go to [major cancer center], but they have
the same trial that we have'… It evens that playing field. So it helps to obtain patients.”
Having access to clinical trials through the CCOP also allows physicians to treat existing
patients in the local market. As one informant explained, “we retain patients here. They kind
of walk them through every step of the way throughout their care.” The importance of
market share benefits for the business case was best described by one informant who stated,
“I think about the ability [of the CCOP organization] to add more patients and getting
through the doors, [and] that helps that positive bottom line.”
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3) Philanthropic Support: The third sub-theme that emerged was the role of CCOP
participation in attracting support from the philanthropic community. While oncology
services, relative to other services, are traditionally well-supported by the philanthropic
community, informants across the study sites believed that being part of a CCOP
organization further enhanced the CCOP-affiliated providers' abilities to attract donations.
One senior administrator described this relationship: “We have a long tradition of being
well-supported by the philanthropic community in cancer treatment. Cancer care is one of
the areas that people like to support, and we've benefitted from that. We think the CCOP has
helped us -- it's helped us as an underpinning to the overall stability of the program.” These
donations can benefit the CCOP-affiliated providers generally, or can be directed by the
donor for a specific purpose, such as oncology research. When directed toward the latter,
donations can be used to subsidize CCOP organization operations. In fact, two of the CCOP-
affiliated providers reported being able to draw on these donated funds directly to balance
any shortfalls in the program.
4) Other Revenues: While downstream revenue, market share, and philanthropy were
predominant sub-themes, there were several other important indirect financial benefits cited
by our informants. For example, one study site suggested performance-based payments for
improved cancer care quality could be attributable to CCOP participation. Similarly, avoided
costs associated with improved efficiency and quality gains in cancer care were also
suggested as indirect financial benefits of CCOP participation. Finally, several informants
mentioned avoided turnover costs due to higher employee satisfaction among physicians and
nursing staff working with the CCOP, and noted that this was an important indirect benefit
of CCOP participation.
The Need for A Business Case
The final question we explored in this study was about the importance of a business case to
generate or sustain executive leadership support for the CCOP organization within the
CCOP-affiliated provider's organization. Across all sites, informants perceived the business
case as increasingly important, particularly given the strained economic climate existent
during the study period. CCOP-affiliated providers did not view research as a “way to make
money,” but at the same time suggested that, at a minimum, the CCOP organization would
need to break-even or demonstrate a slightly positive ROI, inclusive of direct and indirect
benefits, to maintain organizational support from the CCOP-affiliated provider. The
importance of a business case was particularly acute for the site that had recently applied to
become a CCOP organization. A senior administrator at this site said, “Oh, it [a business
case] would absolutely be imperative. There would be no way that we would go down this
path without a sound financial business plan for doing clinical research and expected ROI.
And you know, at one, three, five years out from there.” Another administrator at the same
site echoed this sentiment: “I think that, again, in this economy, that approval of anything
without showing that you're either going to have positive revenue, or at least not a loss, is
going to be critical.” Similarly, informants in mature CCOP organizations recognized the
growing importance of a business case. A physician affiliated with one mature CCOP
organization explained, “I think it's [the business case] going to be needed. I mean, the
hospital's had to undergo so many cost cuts to stay solvent. We're no way going to be
immune to that unless we can justify our position with the downstream revenue.”
Nonetheless, not all informants agreed that a business case was an absolute requirement for
CCOP participation. As one informant explained this contrasting view, “That's a difficult
question to answer because our expectation, especially from the federal funding perspective,
is that we don't necessarily have positive. I mean our goal isn't to make a lot of money off of
it.” While a majority of interviewees shared the perspective that a business case was indeed
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important, there was also collective sentiment that other reasons for participating in a CCOP,
such as the multiple indirect benefits of participation described above as well as altruistic
reasons, might lessen the strict requirement to demonstrate a financial business case.
Additional representative quotes showing these perspectives about the need for a business
case are presented in Table 3.
DISCUSSION AND CONCLUSION
The lack of an established business case may result in provider reluctance to participate in
clinical trials research through PBRNs such as the CCOP, particularly when financial
resources are constrained. However, results from this study suggest that it may be possible
to establish a business case if both direct and indirect financial benefits are identified and
included in the analysis, and the time horizon is long enough to allow those benefits to be
realized.
Although none of the study sites reported any formal attempt to demonstrate a business case
(possibly because many of the CCOP organizations were established during more favorable
economic conditions), most conceded that such evidence would be increasingly necessary to
maintain financial and in-kind support from the senior leadership of these CCOP-affiliated
providers. The need for a demonstrated business case was most acutely recognized by the
study site that had recently applied, but not yet become a CCOP. The recent economic
downturn, combined with escalating pressure on hospital and provider organizations to
manage costs, was perceived as driving the need for CCOP organizations to demonstrate a
business case to their affiliated providers. Our findings echo those of previous studies that
have shown the need for clinical or quality-improvement health programs to demonstrate a
business case to generate or maintain organizational support (Leatherman et al., 2003;
Reiter, Kilpatrick, Greene, Lohr, & Leatherman, 2007; Song et al., 2011b), and the
importance of including indirect benefits in making the business case.
Our findings should be taken in the context of the study limitations. This study included five
CCOP organizations that were selected on the basis of organization maturity in a CCOP
organization. Because these organizations were already part of a CCOP organization or had
recently applied to become a CCOP organization, it is possible our findings may reflect
participants' desire to justify their decision to participate in the CCOP organization despite
formal evidence of a business case. However, we did find participants across all sites who
reported that a positive financial return was unlikely; even among this group we found
consistency about the reported financial benefits of CCOP participation. Also, the potential
direct and indirect financial benefits we identified may not apply to all CCOP organizations,
potentially limiting the generalizability of our findings to all CCOP organizations. Finally, it
is important to recognize that clinical trials are not for everyone, rather patient participation
is completely voluntary and physicians need to agree that the question under study is valid to
their practice. As such, there should not be an expectation that most patients will participate
in clinical trials, nor will most physicians be comfortable with the conduct of all trials. This
study was meant to look beyond physician commitment to the clinical benefits that could
results from clinical trials participation and explore the incentives for long-term
sustainability of provider-based research networks such as the CCOP.
PRACTICE IMPLICATIONS
Although this study focuses on the business case for provider participation in CCOP
organizations, the results are relevant to other federally-funded PBRNs outside of oncology,
and salient to those considering participation in any clinical trials research. The costs and
benefits described by study participants, for example, salaries of research personnel and
downstream revenue, were generally not unique to cancer. Since the CCOP may serve as a
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model for other PBRNs, our results, together with the existing literature, can be applied by
organization and policy leaders to identify and communicate elements of the business case
to encourage expansion and sustainability of provider participation in clinical trials research.
Our results can also be applied more generally to clinical and quality-improvement
initiatives to develop appropriate and practical strategies for evaluating such programs'
business case (Leatherman et al., 2003; Reiter et al., 2007; Song et al., 2011; Song et al.,
2011b; Kilpatrick et al., 2005; Bailit & Dyer, 2004). By establishing a business case,
providers will be free to move beyond financial hurdles and to realize other benefits of
clinical research participation, including the satisfaction that comes with providing effective
care to local populations, achieving accrual goals, increasing patient satisfaction, and being
recognized as a leader in health care.
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Table 1
CCOP Case Study Site Characteristics
























CCOP= Community Clinical Oncology Program; NCI/DCP = National Cancer Institute Division of Cancer Prevention
*
Accruals include patient accruals to all NCI-sponsored clinical trials, not only CCOP trials.
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Table 2
Case Study Sites' Characterizations of the Business Case for Provider Participation in the CCOP
Representative Verbatim Quotes
Short-term versus long-
term business case for
CCOP participation.
“Absolutely not. No, no, no, no. Short term to me would mean less than a couple of years and it actually has taken
us a really long time to come into a positive budget. Probably, I would say eight years.”
“No, I think the financial gain is a long haul sort of thing. I don't know that just putting together some sort of
CCOP program and putting patients on trial is going to make you rich in a year or two. But I think that as you
establish yourself in the community for providing high quality of care, I think people see that.”
“Yes, absolutely. And I think it's been underestimated. And that's kind of the case I'm trying to make. The fact is,
we're meeting with the COO[Chief Operating Officer] to go over that issue that it's underappreciated. And then it
needs to be factored in, when they're sitting down. And they should not be looking at this is just a negative on the




“It would be more on the intangible sides that we would probably try to document and look at it there. Because
right now, the best thing we can do around clinical trials, it's not just cancer, but different areas, is that if you break
even, you are doing pretty good on clinical research.”
“You know, I'd like to think that it's not a money loser and that there truly is some portion of those patient revenues
that would not be here if we did not have the CCOP. The prestige it affords the institution, you know? The ability
to make those protocols available to the patients who would seek them out. And so I'd like to say that it at least nets
a zero.”
“Oh, absolutely. I absolutely believe that. And the reason I do is because I sort of make this analogous to our
genetic counseling program. We have a very extensive genetic counseling program… if you look at downstream
revenue and you look at tests that were ordered or patients that came to us simply because we have a genetic
counseling program, it is certainly a very, very profitable service. And I think the same thing about research.”
CCOP= Community Clinical Oncology Program
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Table 3
Case Study Sites Characterizations of the Need for a Business Case
Representative Verbatim Quotes
A business necessary
“I just think it's unrealistic to think that the CCOP program is going to continue unless you can say you're at least
breaking even. And I don't think there's anything wrong with saying you made a couple extra bucks as long as that
money is going back into the CCOP system… So I think you have to be realistic. This has got to start being run like
a business. That's the problem with medicine today--it's not run as a business. And the CCOP program is not going
to be immune from that.”
“…in this economy, that approval of anything without showing that you're either going to have positive revenue, or
at least not a loss, is going to be critical.”
“If we were starting today, that would be a lot harder because obviously hospitals are struggling to maintain. And in
these economic times and with the uncertain economic future and healthcare reimbursement returns coming, so I
think that if we were doing that today, it would even be of much greater importance in terms of getting it going.”
“Yeah, absolutely. I mean I think as a private, not-for-profit, clearly one thing I've learned at [CCOP-affiliated
hospital] is everything has a business plan. And yeah, no, I think clinical trials and certainly the CCOP was part of a
business plan. Not a stand-alone plan, but part of a business plan for cancer services in general. The research
services.”
“I guess from an observer, I don't know that I would say yes. Only because I've seen [affiliated hospital] step up to
the plate when there was a potential for loss. So if they were only looking for a positive financial return, it doesn't
seem like they'd be putting much effort into cooperative group research at all. But again, that's an observer's
perspective.”
A business case is
unnecessary
“You know, I don't know. I think that it's part of the organization's culture: innovation. So the balancing, it's the
research participation that is very important. And again, this is intellectually. The research is extremely important,
and it's part of our vision and strategy. Then you probably forego investments in other areas because you believe
this investment will further your movement towards your vision. So once again, it's a trade-off, if you will.”
“So I guess that the question really is, do I think that you have to have a CCOP that needs to make money? I would
say no. But I do think it should break even. That sounds like it's not even doing that.”
CCOP= Community Clinical Oncology Program
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